Reminder: Ordering arrangements for Inclisiran (Leqvio®)

From September 2021, a new section (Part VIIIC) was included in the Drug Tariff setting out payment arrangements for products with a nominal price (i.e where the purchase price of the product is significantly lower than its NHS list price).

Products listed in Part VIIIC are available at nominal prices because of commercial deals in place between the manufacturer or supplier and the NHS England and NHS Improvement (NHSE&I) which allows manufacturers to supply a drug to the NHS at a reduced cost compared to its published NHS list prices as authored in the NHS Dictionary of Medicines and Devices (dm+d).

Part VIIIC currently outlines the reimbursement price of one product, Inclisiran (Leqvio®), under such a commercial arrangement.

Contractors should not expect to incur any additional charges or fees when ordering Inclisiran from AAH UK. The product will be available to order at the nominal charge of £45 per pack, as agreed within the commercial agreement between Novartis and NHSE&I. However, contractors who are unable to source products listed in Part VIIIC at or below the basic price, or who are the subjected to additional charges when purchasing the products listed in this Part, may request a review of the basic price and repayment of any additional costs incurred. The review requires the following steps to be taken:

• If there are any issues with the supply, ordering and pricing of the product, contractors must contact AAH UK in the first instance.
• This can be escalated to Novartis via the wholesaler if appropriate, and a resolution to all issues raised will be sought within 5 working days from receipt.
• Should no resolution be identified by the suppliers within 5 working days of receipt, then contractors should escalate the issue to PSNC who will work in collaboration with NHSE&I and Novartis to seek a resolution to issues raised.
• To support the handling of the review, contractors are required to submit evidence of any difficulties experienced including issues with pricing or supply. Any claims and supporting evidence will then be referred by PSNC to Department of Health and Social Care.

Following a successful review, where pricing issues are identified, any adjustments will be applied by the NHS Business Service Authority (NHSBSA) to the contractors account at the earliest possible payment date.

To escalate a pricing or supply issue with Inclisiran please contact info@cpe.org.uk